The patient population STEMREGEN is courting is not, strictly speaking, sick. They are middle-aged and older adults worried about the slow accounting of aging: a knee that no longer recovers from a weekend hike, a back that stiffens after a long flight, a sense that the body's repair budget has quietly been cut. To that audience, the Austin company is selling a capsule called Release, a blend of plant extracts that the company says supports the mobilization of stem cells from bone marrow into circulation [Stemregen website, retrieved 2025]. The pitch is not that the pill cures a disease. The pitch is that more circulating stem cells might let the body do more of its own repair work.
That is a careful framing, and it has to be. STEMREGEN's products are marketed as dietary supplements, not drugs, which means they sit under the FDA's DSHEA framework rather than the agency's drug-approval pathway. Supplements in the United States can make structure-function claims (supporting the body's repair system, for example) but cannot claim to treat, diagnose, or cure a specific disease without crossing into territory that requires an Investigational New Drug application and the clinical phases that follow. The company's website language hews to the supplement side of that line, repeatedly framing the product as supporting circulating stem cell counts rather than treating any named condition [Stemregen website, retrieved 2025].
The bet
Founder Christian Drapeau, who now serves as Chief Science Officer, has spent more than two decades on what he calls Endogenous Stem Cell Mobilization, the idea that bone marrow can be coaxed to release more of its own stem cells into the bloodstream through specific botanical compounds [Stemregen history page, retrieved 2025]. The company's flagship product, Release, combines what STEMREGEN describes as multiple clinically tested plant extracts that support both stem cell release and migration [Stemregen product page, retrieved 2025]. A second product line includes a proprietary aloe extract the company brands as StemAloe, which it says is documented to support stem cell release from the bone marrow [Stemregen ingredients page, retrieved 2026]. Distribution is direct-to-consumer through the company's website, supplemented by an approved reseller program for practitioners and affiliates.
The commercial wedge here is real. Customers who already buy NAD precursors, peptides, and longevity-branded supplements are a fast-growing slice of the wellness market, and they are willing to pay premium prices for products with a coherent mechanistic story. STEMREGEN's story (your own stem cells, mobilized by plants you can pronounce) is unusually clean for a category often muddled by ingredient stacks of twenty-plus compounds.
Why it could be big
The company says it is now trusted by more than 5,000 customers [Stemregen website, retrieved 2025] and was named to the 2025 Inc. 5000 list of fastest-growing private companies in America [Inc.com, retrieved 2026]. That recognition typically requires several years of compounding revenue growth, which suggests the DTC engine is working without disclosed outside venture capital. STEMREGEN has also returned as title sponsor of the 2026 Biohacking Conference [Yahoo Finance], a venue that puts the brand directly in front of its highest-intent buyers: practitioners and consumers already spending heavily on longevity protocols.
Customers (reported) | 5000 | people
Employees (Prospeo) | 16 | people
Employees (ZoomInfo range midpoint) | 30 | people
The upside case is straightforward. If even a fraction of the longevity-curious consumer base adopts a stem cell mobilization protocol as a daily habit, the recurring revenue math on a subscription supplement business becomes attractive quickly. Founder-led brands in adjacent categories have built nine-figure revenue lines on similar mechanics.
Standard of care today
For the conditions STEMREGEN's customer testimonials gesture at (joint discomfort, slow recovery from exercise, the general wear of aging), the actual standard of care is unglamorous. Clinicians recommend resistance training, protein-adequate nutrition, sleep, and management of cardiometabolic risk factors. For specific orthopedic injuries, physical therapy and, when indicated, corticosteroid or hyaluronic acid injections remain first-line. Autologous stem cell therapies exist in clinical practice, mostly in orthopedics and mostly outside FDA-approved indications, and the agency has repeatedly warned consumers about unapproved stem cell clinics. An oral supplement that claims to influence endogenous stem cell behavior is a different category entirely, and one without an established peer-reviewed body of randomized controlled trial evidence published in major clinical journals.
The team and traction
Drapeau remains the scientific face of the company. In April 2024, STEMREGEN announced a leadership expansion, with Ryan Riley appointed as Chief Executive Officer and additional hires brought in to support growth [PRNewswire, April 2024; The Org, retrieved 2026]. Headcount sits in the 11-to-50 range, with one data provider listing 16 employees across seven departments [Prospeo.io, retrieved 2026; ZoomInfo, retrieved 2026]. The hand-off of operating responsibility from a scientist-founder to a commercial CEO is a common and usually healthy step for a DTC brand entering a scaling phase.
The honest counterfactual
Skeptics will press on the evidence base. The company's product claims rest on its own research program and on what it describes as clinically tested extracts [Stemregen product page, retrieved 2025], and the broader peer-reviewed literature on oral botanicals causing meaningful, durable increases in circulating hematopoietic or mesenchymal stem cells in humans is thin compared to, say, the evidence base for statins or GLP-1 agonists. Regulators in both the United States and Europe have grown more attentive to supplement marketing that edges toward therapeutic claims, and the FDA has taken enforcement action against companies whose websites or affiliates stray across the disease-claim line. The bull answer is that STEMREGEN has, by the available record, kept its on-label language within structure-function territory and built a customer base willing to pay for the protocol on its own terms. Inc. 5000 inclusion suggests those customers are renewing.
What to watch
The next twelve months will tell us whether STEMREGEN's growth is a wellness-conference moment or a durable consumer health brand. The signals to track: any peer-reviewed publication tied to the company's extracts, particularly a randomized trial measuring circulating CD34+ cells; expansion of the practitioner reseller channel; and whether the post-2024 leadership team raises outside capital to accelerate, which would be the first formal investor validation of the thesis. For a company asking aging adults to trust their repair system to a daily capsule, the most valuable thing it can ship next is not a new SKU. It is data.
Pulse Raman, Startuply